Since a prominent role of DRD3-signalling in CD4+ T-cells has been observed in the development of PD in mouse models (13, 32), and the systemic DRD3-antagonsim has been proven to attenuate neurodegeneration and motor impairment in different animal models of PD (23), we next aimed to test the therapeutic potential of the selective inhibition of DRD3-confined to CD4+ T-cells. The gene discussed is CD4; the disease is Parkinson disease.